Almac Group Supports Two COVID-19 Clinical Studies in Sub-Saharan Africa
May 28, 2020
Grant awarded from the COVID-19 Therapeutics Accelerator, an Initiative by the Bill & Melinda Gates Foundation, Wellcome and Mastercard
Almac Group, the global contract development and manufacturing organisation, has received a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a treatment for Coronavirus. This was awarded from the COVID-19 Therapeutics Accelerator, an initiative by the Bill & Melinda Gates Foundation, Wellcome and Mastercard.
Almac Clinical Services is providing a full range of clinical trial solutions from protocol through to patient delivery, whilst Almac Sciences is providing analytical support, direct from its global headquarters in Craigavon, Northern Ireland. In an effort to expedite the drug development process, Almac Clinical Services has received the active drug and is providing over encapsulation services, manufacturing a placebo match, packaging and labelling the supplies to support this blinded clinical trial. Almac Sciences is conducting rigorous analytical and stability testing for the investigational drug.
Dr. Robert Dunlop, Managing Director and President, Almac Clinical Services commented. “This virus is threatening peoples’ lives and livelihoods and nowhere worse than in the poorer regions of the world. Almac’s global capabilities and expertise enables us to play our part and support efforts to find a vaccine and/or treatment for Coronavirus. We are delighted to be awarded this grant from the COVID-19 Therapeutics Accelerator and to be supporting these clinical studies in Sub-Saharan Africa.”
Almac Clinical Services will ship all supplies to the clinical site with onward management of logistics and distribution of quality drug for delivery safely to patients. This Covid-19 study is being led by an African Principal Investigator. In addition, Almac is supporting a second open label clinical study through the distribution of commercial packs to a pharmacy in South Africa. Due to its comprehensive range of innovative and flexible services, Almac was approached to support these urgent clinical studies by R&D Supply Chain Advisors, Brizzey LLC.
The COVID-19 Therapeutics Accelerator is an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard, with funding from an array of public and philanthropic donors to speed up the response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally. Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
*Source Almac Group,
Nkemnji Global Tech
Pan African Visions | November 23, 2020 5:23 pm
Pan African Visions | November 23, 2020 5:05 pm
Pan African Visions | November 23, 2020 4:59 pm
Pan African Visions | November 22, 2020 1:59 am
African Energy Chamber to Gather Industry Stakeholders within the CEMAC Region Ahead of 2021 Recovery
November 23, 2020 6:30 pm
Oil and Gas Discoveries and Activity in Southwest Africa Set to Open New Basins for Development and Trigger Big Investments in Namibia, Angola and South Africa
November 23, 2020 6:18 pm
November 23, 2020 5:23 pm
November 23, 2020 5:12 pm
November 23, 2020 5:05 pm